The past couple of years have been absolutely phenomenal for technology stocks, which is evident from the 90% gains clocked ...
The reduced guidance for earnings per share (EPS) was even more concerning, with the new high-end estimate of $12.55 where prior guidance called for $15.60 at the high end. During Q3, Eli Lilly ...
Revenue guidance for Q4 2024 of $13.3-14.3 billion, coupled with expected non-GAAP earnings per share of $0.12, indicates ...